DENTSPLY SIRONA Bilan de santé
Santé financière contrôle des critères 3/6
DENTSPLY SIRONA has a total shareholder equity of $3.1B and total debt of $2.1B, which brings its debt-to-equity ratio to 69.2%. Its total assets and total liabilities are $6.9B and $3.8B respectively. DENTSPLY SIRONA's EBIT is $267.0M making its interest coverage ratio 3.6. It has cash and short-term investments of $279.0M.
Informations clés
69.2%
Ratio d'endettement
US$2.12b
Dette
| Ratio de couverture des intérêts | 3.6x |
| Argent liquide | US$279.00m |
| Fonds propres | US$3.06b |
| Total du passif | US$3.83b |
| Total des actifs | US$6.90b |
Mises à jour récentes de la santé financière
We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24
Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07Recent updates
DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Dentsply Sirona hires Simon Campion as president, CEO
Aug 25Dentsply Sirona receives noncompliance notice from Nasdaq
Aug 16Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument
Jul 18Analyse de la situation financière
Passif à court terme: XRAY's short term assets ($1.8B) exceed its short term liabilities ($1.3B).
Passif à long terme: XRAY's short term assets ($1.8B) do not cover its long term liabilities ($2.5B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: XRAY's net debt to equity ratio (60.1%) is considered high.
Réduire la dette: XRAY's debt to equity ratio has increased from 28.9% to 69.2% over the past 5 years.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: Whilst unprofitable XRAY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Prévisions de trésorerie: XRAY is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.5% per year.